ANI Pharmaceuticals Inc
ANIP82.850USD
+0.020+0.02%
Cierre 12/19, 16:00（ET）Cotizaciones retrasadas 15 min
1.86BCap. mercado
48.51P/E TTM
Más Datos de ANI Pharmaceuticals Inc Compañía
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Información de ANI Pharmaceuticals Inc
Símbolo de cotizaciónANIP
Nombre de la empresaANI Pharmaceuticals Inc
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoLalwani (Nikhil Suresh)
Número de empleados897
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección210 Main Street West
CiudadBAUDETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal56623
Teléfono12186343500
Sitio Webhttps://www.anipharmaceuticals.com/
Símbolo de cotizaciónANIP
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoLalwani (Nikhil Suresh)
Ejecutivos de ANI Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-6.68%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Desglose de ingresos
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Otro
73.39%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Otro
73.39%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.11%
Investment Advisor/Hedge Fund
23.24%
Hedge Fund
19.41%
Individual Investor
7.45%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.67%
Bank and Trust
1.33%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
UBS Financial Services, Inc.
401.55K
1.8%
+137.16K
+51.88%
Jun 30, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
427.55K
1.92%
-2.08K
-0.48%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
Ver más
Invesco Pharmaceuticals ETF
Proporción2.63%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción1.63%
Innovator IBD Breakout Opportunities ETF
Proporción1.38%
Innovator IBD 50 Fund ETF
Proporción1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción0.98%
Invesco S&P SmallCap Health Care ETF
Proporción0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción0.92%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.67%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ANI Pharmaceuticals Inc?
Los cinco principales accionistas de ANI Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A. posee 2.37M acciones, lo que representa el 10.64% del total de acciones.
The Vanguard Group, Inc. posee 1.27M acciones, lo que representa el 5.71% del total de acciones.
Meridian Venture Partners posee 1.01M acciones, lo que representa el 4.55% del total de acciones.
State Street Investment Management (US) posee 716.12K acciones, lo que representa el 3.21% del total de acciones.
Esjay L.L.C, posee 632.62K acciones, lo que representa el 2.84% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 2.37M acciones, lo que representa el 10.64% del total de acciones.
The Vanguard Group, Inc. posee 1.27M acciones, lo que representa el 5.71% del total de acciones.
Meridian Venture Partners posee 1.01M acciones, lo que representa el 4.55% del total de acciones.
State Street Investment Management (US) posee 716.12K acciones, lo que representa el 3.21% del total de acciones.
Esjay L.L.C, posee 632.62K acciones, lo que representa el 2.84% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de ANI Pharmaceuticals Inc?
Los tres principales tipos de accionista de ANI Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
¿Cuántas instituciones poseen acciones de ANI Pharmaceuticals Inc (ANIP)?
A fecha de 2025Q4, 507 instituciones poseen acciones de ANI Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 21.97M, lo que representa el 100.49% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -2.78%.
¿Cuál es la mayor fuente de ganancias de ANI Pharmaceuticals Inc?
El FY2025Q2, el segmento empresarial Sales of generic pharmaceutical products generó la ganancia más alta para ANI Pharmaceuticals Inc, ascendiendo a 90.30M y representando el --% de la ganancia total.
